Skip to content
PubMed This is a summary of 25 peer-reviewed journal articles Updated
Nephrology · IgA Nephropathy

How to Tell Primary IgA Nephropathy From Secondary IgA

At a Glance

Primary IgA nephropathy is diagnosed when IgA deposits in the kidney, symptoms, and test results are not better explained by another illness. Doctors check for liver, autoimmune, infectious, bowel, and medication-related causes because treatment differs.

Finding IgA deposits in your kidneys during a biopsy is a crucial piece of your diagnostic puzzle, but it does not automatically mean you have primary IgA nephropathy (IgAN). The diagnosis of primary IgAN is a “clinicopathologic” diagnosis. This means doctors combine the biopsy results—typically showing IgA-dominant deposits in the mesangium (the central supportive tissue of the kidney filters)—with your lab tests and symptoms [1]. Crucially, primary IgAN is diagnosed only when no other underlying systemic illness is found to be the cause [1] [2].

To ensure you receive the right care, doctors must look for secondary IgA deposition—situations where another health condition drives the IgA buildup [1].

Why Do Secondary IgA Deposits Happen?

In primary IgAN, your body produces an abnormally shaped version of the IgA antibody (galactose-deficient IgA1) that clumps together and triggers kidney inflammation [1]. Secondary IgA deposits occur differently. When you have chronic liver disease, severe infections, or certain autoimmune conditions, your body’s immune regulation and its ability to clear circulating IgA can be altered, leading to deposits in the kidney [3] [4]. Sometimes, small amounts of IgA can even be “incidental,” meaning they are present but not actually causing your kidney damage [5].

How Doctors Check for Secondary Causes

Your care team will review your history and may order targeted tests to look for recognized secondary causes [1]. Finding IgA deposits does not mean you have one of these conditions; the workup is individualized based on your unique symptoms.

1. Chronic Liver Disease

The liver helps clear IgA complexes from your blood. If it is damaged, IgA can accumulate [3]. Doctors will ask about heavy alcohol use and check for signs of cirrhosis (liver scarring) and viral hepatitis (Hepatitis B and C) [6] [7].

2. Autoimmune and Rheumatologic Diseases

IgA deposits can be part of broader autoimmune diseases. Important considerations include:

  • IgA Vasculitis: This condition shares the same kidney findings as primary IgAN but causes systemic symptoms like a purple spotted rash (palpable purpura), joint pain, and abdominal pain [3].
  • Lupus (Systemic Lupus Erythematosus): Lupus nephritis can closely mimic IgAN [8]. Doctors will evaluate you for joint pain or rashes and check specific blood markers, such as ANA (antinuclear antibodies) and complement levels [9].

3. Active Infections

A severe, ongoing bacterial infection (such as a staph infection on the skin or an infection in the heart valves) can cause an intense immune reaction known as IgA-dominant infection-related glomerulonephritis [10]. This is different from the temporary, visible blood in the urine (hematuria) that many primary IgAN patients experience during a standard common cold. To rule out an active infection-related cause, doctors will check for recent fevers, skin infections, or antibiotic use, and monitor your blood complement levels [11]. They may also screen for HIV, which is associated with several kidney conditions [12].

4. Gastrointestinal Conditions

Bowel diseases like inflammatory bowel disease (IBD) and celiac disease are associated with secondary IgA deposits [13] [14].

Important Safety Note on Celiac Testing: If celiac disease is suspected, doctors may check your blood for tissue-transglutaminase (tTG) IgA. This test should generally be interpreted with a total-IgA measurement to avoid false negatives caused by IgA deficiency [13]. Do not start a gluten-free diet before testing, as this can make the test inaccurate. Always wait for your clinician’s guidance.

5. Medication Exposures

Rarely, certain medications, such as anti-TNF biologics used for inflammatory diseases (e.g., infliximab or adalimumab), have been associated with secondary IgA deposits [15] [3].

Medication Safety: These associations are uncommon and do not definitively prove the drug caused the problem. Never stop an effective prescribed medication on your own. Discuss the risks and timing with your prescribing specialist and nephrologist.

What the Biopsy Can and Cannot Tell You

While the biopsy is essential, no single staining pattern perfectly identifies the cause [1]. Pathologists look for clues under microscopes, but they must be interpreted alongside your clinical picture:

  • “Full-house” staining: This means the biopsy lights up with many different immune proteins (like IgG, IgM, and C1q). It raises high suspicion for lupus but is not absolute proof, as it can happen in other immune complex diseases [9] [8].
  • Subepithelial humps: These bump-like structures seen on electron microscopy support the possibility of an infection-related cause, but they do not single-handedly prove there is an active bacterial infection [10] [11].

Why the Distinction Matters for Your Treatment Plan

Primary and secondary diseases require very different treatment approaches.

For primary IgAN, treatment generally begins with optimized supportive care, such as medications to control blood pressure and reduce urine protein (proteinuria) [16] [17]. Stronger immunosuppressants (like corticosteroids) are not routine for everyone; they carry risks like severe infections and metabolic issues, and are typically reserved only for selected patients at a meaningful risk of kidney failure [17] [18].

For secondary IgA deposition, treatment focuses on the underlying cause. How immunosuppressants are used depends entirely on the condition:

  • If an active infection is driving the kidney inflammation, giving immunosuppressants could weaken your immune system and be highly dangerous [19] [18]. Instead, antibiotics and source control are required [19].
  • Conversely, if your secondary cause is an autoimmune disease like lupus or severe IgA vasculitis, specialist-directed immunosuppression is often a critical and necessary part of the treatment [20] [21].
  • For liver or gastrointestinal causes, treating the underlying illness (such as antiviral meds for hepatitis or managing IBD) is the priority [22] [23].

While successfully treating the root cause of a secondary condition can halt ongoing kidney injury, it is not a guaranteed cure [24]. Established scarring, reduced kidney function, or proteinuria may persist, requiring long-term monitoring of your blood pressure and kidney function by your nephrologist [25].

Common questions in this guide

How do doctors distinguish primary IgA nephropathy from secondary IgA deposition?
Doctors combine the kidney biopsy with your symptoms, blood and urine results, and medical history. Primary IgA nephropathy is considered when IgA-dominant deposits are present in the mesangium and no other systemic illness better explains the kidney injury.
Do IgA deposits on a kidney biopsy always mean I have primary IgA nephropathy?
No. Similar deposits can occur with liver disease, autoimmune conditions, severe infections, gastrointestinal disease, certain medications, or incidentally without causing the kidney damage. The biopsy must be interpreted with the broader clinical picture.
What conditions can cause secondary IgA deposits in the kidneys?
Possible secondary settings include chronic liver disease or viral hepatitis, lupus or IgA vasculitis, severe bacterial infections, inflammatory bowel disease, and celiac disease. Rare medication-related associations have been reported with anti-TNF biologics such as infliximab or adalimumab.
What do full-house staining and subepithelial humps mean on an IgA nephropathy biopsy?
Full-house staining means several immune proteins are present and can raise suspicion for lupus-related kidney disease. Subepithelial humps can support an infection-related cause. Neither finding proves the diagnosis by itself, so doctors compare them with symptoms, laboratory results, and infection evaluation.
What tests might be used to look for a secondary cause of IgA deposits?
Depending on your history, doctors may check for liver disease and hepatitis, autoimmune markers such as ANA and complement levels, signs of active infection, and conditions affecting the bowel. If celiac disease is suspected, a tissue-transglutaminase IgA test is generally interpreted with a total IgA level, and you should not start a gluten-free diet before testing unless your clinician advises it.
How does the cause of IgA deposits affect treatment?
Primary IgA nephropathy usually begins with supportive kidney care, including blood pressure and protein control, while stronger immune-suppressing treatment is reserved for selected higher-risk patients. Secondary disease is treated by addressing the underlying problem; active infections generally require antibiotics and source control rather than immunosuppression, whereas autoimmune causes may require specialist-directed immunosuppression.

Get notified when new evidence is published on Immunoglobulin A nephropathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (25)
  1. 1

    IgA Nephropathy in Adults: A Review.

    Stoneman S, Teh JW, O'Shaughnessy MM

    JAMA 2026; (335(9)):799-813 doi:10.1001/jama.2025.25020.

    PMID: 41587026
  2. 2

    The Diagnostic Conundrum of Glomerular Crescents With IgA Deposits.

    Kitamura M, Almaani S, Challa B, et al.

    Kidney international reports 2023; (8(3)):507-518 doi:10.1016/j.ekir.2022.12.024.

    PMID: 36938067
  3. 3

    Secondary IgA Nephropathy and IgA-Associated Nephropathy: A Systematic Review of Case Reports.

    Tota M, Baron V, Musial K, et al.

    Journal of clinical medicine 2023; (12(7)) doi:10.3390/jcm12072726.

    PMID: 37048809
  4. 4

    Immunostaining for galactose-deficient immunoglobulin A is not specific for primary immunoglobulin A nephropathy.

    Cassol CA, Bott C, Nadasdy GM, et al.

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2020; (35(12)):2123-2129 doi:10.1093/ndt/gfz152.

    PMID: 31369128
  5. 5

    Glomerular Galactose-Deficient IgA1 Deposition in 192 Autopsy Cases in Japan.

    Nihei Y, Aoki R, Matsuzaki K, et al.

    Nephrology (Carlton, Vic.) 2025; (30(9)):e70128 doi:10.1111/nep.70128.

    PMID: 40968461
  6. 6

    Clinical Presentation, Pathological Spectrum, and Outcomes of Alcoholic Cirrhosis-Related Immunoglobulin A Nephropathy.

    Ronsin C, Braud P, Kandel-Aznar C, et al.

    Kidney international reports 2024; (9(5)):1369-1378 doi:10.1016/j.ekir.2024.02.1397.

    PMID: 38707818
  7. 7

    Liver Disease-Associated Glomerulopathies.

    Kanduri SR, Peleg Y, Wadhwani S

    Advances in kidney disease and health 2024; (31(2)):147-156 doi:10.1053/j.akdh.2023.11.002.

    PMID: 38649219
  8. 8

    Sensitivity and Specificity of Pathologic Findings to Diagnose Lupus Nephritis.

    Kudose S, Santoriello D, Bomback AS, et al.

    Clinical journal of the American Society of Nephrology : CJASN 2019; (14(11)):1605-1615 doi:10.2215/CJN.01570219.

    PMID: 31653670
  9. 9

    Diagnostic Utility of Galactose-Deficient Immunoglobulin A1 Immunostaining in the Differentiation of Lupus Nephritis and Immunoglobulin A Nephropathy.

    Bu L, Ye B, Kouri AM, Kim Y

    Glomerular diseases 2021; (1(1)):34-39 doi:10.1159/000511056.

    PMID: 36751490
  10. 10

    Clinicopathological and prognostic study of IgA-dominant postinfectious glomerulonephritis.

    Huang Z, Chen B, Zhou Y, et al.

    BMC nephrology 2021; (22(1)):248 doi:10.1186/s12882-021-02462-3.

    PMID: 34225678
  11. 11

    Staphylococcus Infection-Associated GN - Spectrum of IgA Staining and Prevalence of ANCA in a Single-Center Cohort.

    Satoskar AA, Suleiman S, Ayoub I, et al.

    Clinical journal of the American Society of Nephrology : CJASN 2017; (12(1)):39-49 doi:10.2215/CJN.05070516.

    PMID: 27821389
  12. 12

    HIV-associated Immune Complex Kidney Disease with C3-dominant Deposition Induced by HIV Infection after Treatment of IgA Nephropathy.

    Kawakita C, Kinomura M, Otaka N, et al.

    Internal medicine (Tokyo, Japan) 2019; (58(20)):3001-3007 doi:10.2169/internalmedicine.2439-18.

    PMID: 31243235
  13. 13

    IgA Nephropathy as the Initial Presentation of Celiac Disease in an Adolescent.

    Slavin SF

    Pediatrics 2021; (148(4)) doi:10.1542/peds.2021-051332.

    PMID: 34504037
  14. 14

    Prevalence of Inflammatory Bowel Disease and Celiac Disease in Patients with IgA Nephropathy over Time.

    Nurmi R, Pohjonen J, Metso M, et al.

    Nephron 2021; (145(1)):78-84 doi:10.1159/000511555.

    PMID: 33271538
  15. 15

    IgA Nephropathy Associated With Infliximab Treatment in Patients With Crohn's Disease: Study of IgA1 and IgA2 Expression in Glomeruli.

    Mima A, Nakamoto T, Matsuki T, et al.

    In vivo (Athens, Greece) 2025; (39(3)):1731-1738 doi:10.21873/invivo.13975.

    PMID: 40295023
  16. 16

    Intensive Supportive Care plus Immunosuppression in IgA Nephropathy.

    Rauen T, Eitner F, Fitzner C, et al.

    The New England journal of medicine 2015; (373(23)):2225-36 doi:10.1056/NEJMoa1415463.

    PMID: 26630142
  17. 17

    Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.

    Lv J, Wong MG, Hladunewich MA, et al.

    JAMA 2022; (327(19)):1888-1898 doi:10.1001/jama.2022.5368.

    PMID: 35579642
  18. 18

    Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.

    Lv J, Zhang H, Wong MG, et al.

    JAMA 2017; (318(5)):432-442 doi:10.1001/jama.2017.9362.

    PMID: 28763548
  19. 19

    IgA Dominant Infection Related Glomerulonephritis Mimicking Primary IgA Nephropathy in Methicillin-Sensitive Staphylococcus aureus Osteomyelitis.

    Klor B, Acharya PC, Cunningham I, et al.

    International journal of nephrology and renovascular disease 2026; (19()):578405 doi:10.2147/IJNRD.S578405.

    PMID: 42125487
  20. 20

    Clinicopathological characteristics and renal outcomes of IgA nephropathy in systemic lupus erythematosus: a case report and systematic literature review.

    Zhao X, Li Z, Cai G, et al.

    BMC nephrology 2026; (27(1)).

    PMID: 42216130
  21. 21

    IgA Nephropathy With a Membranoproliferative Glomerulonephritis Pattern Associated With Autoimmune Hepatitis: A Case Report.

    Adachi H, Noishiki H, Ehara H, et al.

    Cureus 2026; (18(3)):e105937 doi:10.7759/cureus.105937.

    PMID: 42046613
  22. 22

    Juvenile dermatomyositis with IgA nephropathy: case-based review.

    Mantoo MR, Tripathy SK, Phulware RH, et al.

    Rheumatology international 2019; (39(3)):577-581 doi:10.1007/s00296-018-4229-4.

    PMID: 30552457
  23. 23

    Renal pathological analysis using galactose-deficient IgA1-specific monoclonal antibody is a strong tool for differentiation of primary IgA nephropathy from secondary IgA nephropathy.

    Lee M, Suzuki H, Kato R, et al.

    CEN case reports 2021; (10(1)):17-22 doi:10.1007/s13730-020-00508-3.

    PMID: 32676896
  24. 24

    "Associated" or "Secondary" IgA nephropathy? An outcome analysis.

    Obrișcă B, Ștefan G, Gherghiceanu M, et al.

    PloS one 2019; (14(8)):e0221014 doi:10.1371/journal.pone.0221014.

    PMID: 31398224
  25. 25

    Impact of immunosuppressive therapy on renal and patient survival in rapidly progressive secondary IgA nephropathy.

    Shabaka A, Sevillano ÁM, Vian J, et al.

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2026; doi:10.1093/ndt/gfag158.

    PMID: 42409357

This page is for informational purposes only and does not constitute medical advice. Your nephrologist and other specialists should interpret your biopsy, test results, and treatment plan in the context of your health history.